Investor Diligence and Decision Support
We support VC/CVC teams, Private Equity, Hedge Funds, and other investors with decision-grade intelligence in BioPharma, HealthTech, and AI-enabled healthcare. From fast diligence to ongoing monitoring, we help you validate assumptions, surface risks early, and act with confidence.
From identifying emerging trends and hidden risks to supporting diligence and portfolio decisions, we deliver concise, actionable recommendations that create an edge.
Our work commonly includes:
- Landscape + diligence (science, commercial, competitive dynamics)
- Company/asset profile (TAM, segmentation, growth drivers, value proposition)
- Opportunity/risk assessment (red flags, catalysts, scenarios, mitigations)
- Custom research aligned to your thesis and timelines (deal-specific questions, thesis validation, monitoring)
- Primary intelligence (targeted KOL and stakeholder interviews to resolve the specific uncertainties in your thesis)
Typical engagement modes:
- Diligence Sprint (5–10 business days)
- Monthly monitoring and brief updates
- Decision workshops and AI-powered wargaming (via LucidWargames) to stress-test theses and quantify scenario risk
Don’t forget to check out our Lucid Diligence Briefs, delivering 60-second theses, questions to ask, red flags and catalysts to watch, linked to trending news.
Want to move faster on your next decision? Contact: info@lqventures.com
February 25, 2026
Lucid Diligence Brief: Astellas collaboration with Vir Biotechnology
February 24, 2026
Endocrinology Video Recap—February 24, 2026
February 24, 2026
Endocrinology Today—February 24, 2026
February 24, 2026
Obesity Today—February 24, 2026
February 23, 2026
Hematology Video Recap—February 23, 2026
February 23, 2026
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel)
February 23, 2026
Hematology Today—February 23, 2026
February 23, 2026
Oncology Today—February 23, 2026
February 22, 2026
Lucid Diligence Brief: Hims & Hers to acquire Eucalyptus
February 20, 2026